Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 12 , ISSUE 1 ( January-February, 2020 ) > List of Articles

REVIEW ARTICLE

Pharmacological Options to Trigger Final Oocyte Maturation in In Vitro Fertilization

Sheetal G Sawankar, Jaideep Malhotra, Neharika M Bora, Pinky R Shah, Narendra Malhotra

Citation Information : Sawankar SG, Malhotra J, Bora NM, Shah PR, Malhotra N. Pharmacological Options to Trigger Final Oocyte Maturation in In Vitro Fertilization. J South Asian Feder Obs Gynae 2020; 12 (1):38-44.

DOI: 10.5005/jp-journals-10006-1753

License: CC BY-NC 4.0

Published Online: 08-08-2020

Copyright Statement:  Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Human chorionic gonadotropin (hCG) has been the gold standard in the induction of final oocyte maturation since the pioneer days of in vitro fertilization (IVF). But owing to its long half-life, it leads to increased risk of ovarian hyperstimulation syndrome (OHSS). Trigger of GnRH agonist is a more physiological trigger, effective, and safe, as it significantly reduces or eliminates risk of OHSS. Newer options of dual trigger and double trigger are discussed in this review, which can be used as modified luteal phase support in patients with expected suboptimal oocyte maturation. Newer pharmaceutical options such as Kissepeptins, key in central regulation of neuroendocrine system, and GnRH release need more studies before being implemented in general practice. This review includes details of various trigger options for final oocyte maturation and about combination of trigger options aiming safe and effective outcomes.


PDF Share
  1. World Health Organization, Prevalence of moderate and severe disability (in millions), by leading health condition associated with disability, and by age and income status of countries. Available at: www.who.int/reproductivehealth/topics/infertility/definitions/en/. Accessed on 1 November 2017.
  2. Shoham Z, Schacter M, Loumaye E, et al. The luteinizing hormone surge—the final stage in ovulation induction: modern aspects of ovulation triggering. Fertil Steril 1995;64(2):237–251. DOI: 10.1016/s0015-0282(16)57717-6.
  3. Voronina E, Wessel G. The regulation of oocyte maturation. Curr Top Dev Biol 2003;58:53–110. DOI: 10.1016/s0070-2153(03)58003-6.
  4. Mao L, Lou H, Lou Y, et al. Behaviour of cytoplasmic organelles and cytoskeleton during oocyte maturation. Reprod Biomed Online 2014;28(3):284–299. DOI: 10.1016/j.rbmo.2013.10.016.
  5. Seibel MM, Smith DM, Levesque L, et al. The temporal relationship between the luteinizing hormone surge and human oocyte maturation. Am J Obstet Gynecol 1982;142(5):568–572. DOI: 10.1016/0002-9378(82)90763-3.
  6. Escrich L, Grau N, de los Santos MJ, et al. The dynamics of in vitro maturation of germinal vesicle oocytes. Fertil Steril 2012;98(5): 1147–1151. DOI: 10.1016/j.fertnstert.2012.07.1116.
  7. Hershko Klement A, Shulman A. hCG triggering in ART: an evolutionary concept. Int J Mol Sci 2017;18(5):E1075. DOI: 10.3390/ijms18051075.
  8. Kayisli UA, Selam B, Guzeloglu-Kayisli O, et al. Human chorionic gonadotrophin contributes to maternal immunotolerance and endometrial apoptosis by regulating fas–fas ligand system. J Immunol 2003;171(5):2305–2313. DOI: 10.4049/jimmunol.171.5.2305.
  9. Yen SS, Llerena O, Little B, et al. Disappearance rates of endogenous luteinizing hormone and chorionic gonadotropininman. J Clin Endocrinolog Metabol 1968;28(12):1763–1767. DOI: 10.1210/jcem-28-12-1763.
  10. Damewood MD, Shen W, Zacur HA, et al. Disappearance of exogenously administered human chorionic gonadotropin. Fertil Steril 1989;52(3):398–400. DOI: 10.1016/s0015-0282(16)60906-8.
  11. Casarini L, Riccetti L, De Pascali F, et al. Estrogen modulates specific life and death signals induced by LH and hCG in human primary granulosa cells in vitro. Int J Mol Sci 2017;18(5):926. DOI: 10.3390/ijms18050926.
  12. Zelinski-Wooten MB, Hutchison JS, TrinchardLugan I, et al. Initiation ofperiovulatoryeventsingonadotrophin-stimulated macaques with varying doses of recombinant human chorionic gonadotrophin. Hum Reprod 1997;12(9):1877–1885. DOI: 10.1093/humrep/12.9.1877.
  13. Detti L, Mitwally MFM, Rode A, et al. Serum human chorionic gonadotropin level after ovulation triggering is influenced by the patient's body mass index and the number of larger follicles. Fertil Steril 2007;88(1):152–155. DOI: 10.1016/j.fertnstert.2006.11.124.
  14. Abdalla HI, Ah-Moye M, Brinsden P, et al. The effect of the dose of human chorionic gonadotropin and the type of gonadotropin stimulation on oocyte recovery rates in an in vitro fertilization program. Fertil Steril 1987;48(6):958–963. DOI: 10.1016/s0015-0282(16)59591-0.
  15. Matorras R, Meabe A, Mendoza R, et al. Human chorionic gonadotropin (hCG) plasma levels at oocyte retrieval and IVF outcomes. J Assist Reprod Genet 2012;29(10):1067–1071. DOI: 10.1007/s10815-012-9826-7.
  16. Tsoumpou Ioanna. Symposium: update on prediction and management of OHSS optimal dose of HCG for final oocyte maturation in IVF cycles: absence of evidence? Reproductive Bio Medicine Online 2009;19(1):52–58. DOI: 10.1016/s1472-6483(10)60045-4.
  17. Driscoll GL, Tyler JP, Hangan JT, et al. A prospective, randomized, controlled, double-blind, double-dummy comparison of recombinant and urinary HCG for inducing oocyte maturation and follicular luteinization in ovarian stimulation. Hum Reprod 2000;15(6): 1305–1310. DOI: 10.1093/humrep/15.6.1305.
  18. Chang P, Kenley S, Burns T, et al. Recombinanthumanchorionic gonadotropin (rhCG) in assisted reproductive technology: Results of a clinical trial comparing two dosesofrhCG(Ovidrel) tourinaryhCG(Profasi) for induction of final follicular maturation in in vitro fertilization-embryo transfer. Fertil Steril 2001;76(1):67–74. DOI: 10.1016/s0015-0282(01)01851-9.
  19. Youssef M, Al-inany H, Aboulghar M, et al. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles. Cochrane Database Syst Rev 2016;4:CD003719. DOI: 10.1002/14651858.CD003719.pub4.
  20. Budev MM, Arroliga AC, Falcone T. Ovarian hyperstimulation syndrome. Crit Care Med 2005;33(10):301–306. DOI: 10.1097/01.ccm.0000182795.31757.ce.
  21. Nakano R, Mizuno T, Kotsuji F, et al. Triggering‘ of ovulation after infusion of synthetic luteinizinghormone releasing factor(LRF). Acta Obstetriciaet Gynecologica Scandinavica 1973;52(3):269–272. DOI: 10.3109/00016347309158325.
  22. Itskovitz J, Boldes R, Levron J, et al. Induction of preovulatory luteinizing hormone surgeand prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril 1991;56(2):213–220. DOI: 10.1016/S0015-0282(16)54474-4.
  23. Hoff JD, Quigley ME, Yen SSC. Hormonaldynamics at midcycle: a reevaluation. J Clin Endocrinol Metabol 1983;57(4):792–796. DOI: 10.1210/jcem-57-4-792.
  24. Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 2004;81(1):1–5. DOI: 10.1016/j.fertnstert.2003. 05.032.
  25. Zelinski-Wooten MB, Hutchison JS, Hess DL, et al. Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin releasing hormone antagonist-treated monkeys. Hum Reprod 1995;10(7):1658–1666. DOI: 10.1093/oxfordjournals.humrep.a136151.
  26. Humaidan P, Polyzos NP, Alsbjerg B, et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: Two prospective randomized controlledmulti-centrestudiesin IVF patients. Hum Reprod 2013;28(9):2511–2521. DOI: 10.1093/humrep/det249.
  27. Melo M, Busso C, Bellver J, et al. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blindstudy. Reproduct Bio Med Online 2009;19(4):486–492. DOI: 10.1016/j.rbmo.2009.06.001.
  28. Parneix I, Emperaire JC, Ruffie A, et al. Comparaisondedifférentsprotocolesdedéclenchement de l'ovulation, par agonistes du GnRH et gonadotrophine chorionique. Gynécol Obstét Fertil 2001;29(2): 100–105. DOI: 10.1016/S1297-9589(00)00064-3.
  29. Andersen CY, Andersen KV. Improving the luteal phase after ovarian stimulation: reviewing new options. Reprod Biomed Online 2014;28(5):552–559. DOI: 10.1016/j.rbmo.2014.01.012.
  30. Humaidan P. Luteal phase rescue in high-risk OHSS patients by GnRHa trig-gering in combination with low-dose HCG: a pilot study. Reprod Biomed Online 2009;18(5):630–634. DOI: 10.1016/s1472-6483(10)60006-5.
  31. Andersen CY, Elbaek HO, Alsbjerg B, et al. Daily low-dose hCG stimulation during the luteal phase combinedwith GnRHa triggered IVF cycles without exogenous progesterone: a proofof concept trial. Hum Reprod 2015;30(10):2387–2395. DOI: 10.1093/humrep/dev184continued daily through the luteal phase.
  32. Engmann L, DiLuigi A, Schmidt D, et al. The use ofgonadotropin-releasing hormone (GnRH) agonist to induce oocyte matura-tion after cotreatment with GnRH antagonist in high-risk patients undergo-ing in vitro fertilization prevents the risk of ovarian hyperstimulationsyndrome: a prospective randomized controlled study. Fertil Steril 2008;89(1):84–91. DOI: 10.1016/j.fertnstert.2007.02.002.
  33. Papanikolaou EG, Verpoest W, Fatemi H, et al. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. Fertil Steril 2011;95(3):1174–1177. DOI: 10.1016/j.fertnstert.2010.09.023.
  34. Castillo JC, Dolz M, Bienvenido E, et al. Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support. Reprod Biomed Online 2010;20(2):175–181. DOI: 10.1016/j.rbmo.2009.11.018.
  35. European Recombinant LH Study Group. Human recombinant luteinizing hormone is as effective as, but safer than, urinary humanchorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. J Clin Endocrinol Metab 2001;86(6):2607–2618. DOI: 10.1210/jcem.86.6.7599.
  36. Seminara SB, Messager S, Chatzidakietal EE. The GPR54 gene as a regulator of puberty. N Engl J Med 2003;349(17):1614–1627. DOI: 10.1056/NEJMoa035322.
  37. Skorupskaite K, George JT, Anderson RA. The kisspeptins-GnRH pathway in human reproductive healthand disease. Hum Reprod Update 2014;20(4):485–500. DOI: 10.1093/humupd/dmu009.
  38. Abbara, Jayasena CN, Nijher GK, Kisspeptins—a novel physiological trigger for oocytematuration in IVF treatment, Human Reproduction; Supplement 1; European Society of Human Reproduction and Embryology 29th Annual Meeting, London, Abstract O-107, 2013.
  39. Abbara A, Jayasena CN, Christopoulos G, et al. Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy. J Clin Endocrinol Metab 2015;100(9):3322–3331. DOI: 10.1210/jc.2015-2332.
  40. Revelli A, Martiny G, Delle Piane L, et al. A critical review of bidimensional and three-dimensional ultrasound techniques to monitor follicle growth: do they help improving IVF outcome? Reprod Biol Endocrinol 2014;12(1):107. DOI: 10.1186/1477-7827-12-107.
  41. Nader S, Berkowitz AS. Study of the pharmacokinetics of human chorionic gonadotropin and its relation to ovulation. J in Vitro Fert Embryo Transf 1990;7(2):114–118. DOI: 10.1007/BF01135585.
  42. Nargund G, Reid F, Parsons J. Human chorionic gonadotropin-to-oocyte collection interval in a superovulation IVF program. A prospective study. J Assist Reprod Genet 2001;18(2):87–90. DOI: 10.1023/a:1026530624575.
  43. Ghasemian F, Faraji R, Asgharnia M, et al. The impact of different time intervals between hCG priming and oocyte retrieval on ART outcomes. Iran J Reprod Med 2013;11(7):559–564.
  44. Castillo JC, Garcia-Velasco J, Humaidan P. Empty follicle syndrome after GnRHa triggering versus hCG triggering in COS. J Assist Reprod Genet 2012;29(3):249–253. DOI: 10.1007/s10815-011-9704-8.
  45. Lok F, Pritchard J, Lashen H. Successful treatment of empty follicle syndrome by triggering endogenous LH surge using GnRH agonist in an antagonist down-regulated IVF cycle. Human Reproduction, 2003;18(10):2079–2081. DOI: 10.1093/humrep/deg421.
  46. Deepika K, Baiju P, Gautham P, et al. Repeat dose of gonadotropin-releasing hormone agonist trigger in polycystic ovarian syndrome undergoing in vitro fertilization cycles provides a better cycle outcome - a proof-of-concept study. J Hum Reprod Sci [serial online] 2017;10(4):271–280. DOI: 10.4103/jhrs.JHRS_102_17.
  47. Meyer L, Murphy LA, Gumer A, et al. Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles. Fertil Steril 2015;104(3):637–642. DOI: 10.1016/j.fertnstert.2015.06.011.
  48. Shapiro BS, Daneshmand ST, Garner FC, et al. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization. Fertil Steril 2008;90(1):231–233. DOI: 10.1016/j.fertnstert.2007.06.030.
  49. Schachter M, Friedler S, Ron-El R, et al. Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study. Fertil Steril 2008;90(4):1087–1093. DOI: 10.1016/j.fertnstert.2007.07.1316.
  50. Decleer W, Osmanagaoglu K, Seynhave B, et al. Comparison of hCG triggering versus hCG in combination with a GnRH agonist: a prospective randomized controlled trial. Facts Views Vis Obgyn 2014;6(4):203–209.
  51. Kim CH, Ahn JW, You RM, et al. Combined administration of gonadotropin- releasing hormone agonist with human chorionic gonadotropin for final oocyte maturation in GnRH antagonist cycles for in vitro fertilization. J Reprod Med 2014;59(1-2): 63–68.
  52. Mahajan N, Sharma S, Arora PR, et al. Evaluation of dual trigger with gonadotropin-releasing hormone agonist and human chorionic gonadotropin in improving oocyte maturity rates: a prospective randomized study. J Hum Reprod Sci 2016;9(2):101–106. DOI: 10.4103/0974-1208.183506.
  53. Ding N, Liu X, Jian Q, et al. Dual trigger of final oocyte maturation with a combination of GnRH agonist and hCG versus a hCG alone trigger in GnRH antagonist cycle for in vitro fertilization: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2017;218:92–98. DOI: 10.1016/j.ejogrb.2017.09.004.
  54. Caixeta ES, Machado MF, Ripamonte P, et al. Effects of FSH on the expression of receptors for oocyte-secreted factors and members of the EGF-like family during in vitro maturation in cattle. Reprod Fertil Dev 2013;25(6):890–899. DOI: 10.1071/RD12125.
  55. Park JY, Su YQ, Ariga M, et al. EGF-like growth factors as mediators of LH action in the ovulatory follicle. Science 2004;303(5658):682–684. DOI: 10.1126/science.1092463.
  56. Kasum M, Kurdija K, Orešković S, et al. Combined ovulation triggering with GnRH agonist and hCG in IVF patients. Gynecol Endocrinol 2016;32(11):861–865. DOI: 10.1080/09513590.2016.1193141.
  57. Haas J, Zilberberg E, Dar S, et al. Co-administrationof GnRH-agonist and hCG for final oocyte maturation (double trigger) in patientswith low number of oocytes retrieved per number of preovulatory follicles-apreliminary report. J Ovarian Res 2014;7(1):77. DOI: 10.1186/1757-2215-7-77.
  58. Griffin D, Benadiva C, Kummer N, et al. Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders. Fertil Steril 2012;97(6):1316–1320. DOI: 10.1016/j.fertnstert.2012.03.015.
  59. Orvieto R. Triggering final follicular maturation- hCG, GnRH-agonist or both, when and to whom? Orvieto Journal of Ovarian Research 2015;8(1):60. DOI: 10.1186/s13048-015-0187-6.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.